Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ivax Generic Zoloft Exclusivity Will Be Unaffected By New FDA Guidance

Executive Summary

Ivax expects to retain the full benefit of the 180-day generic exclusivity period for sertraline in 2006 if it prevails in a challenge of two of Pfizer's patents on Zoloft.
Advertisement

Related Content

Pfizer Zoloft “Authorized” Generic Will Be Available From Ivax By Mid-2006
Generic Paxil Approved By FDA; Apotex Faces Tricky Launch Decision
Teva’s Generic Remeron Exclusivity Cut To Five Months By FDA Rules
180-Day Exclusivity Trigger Change Is Most Important Part Of S 812 – Barr
FDA Citizen Petition Rule On Hold; Pregnancy Label Work Continues
Dr. Reddy’s Omeprazole Case Vs. FDA Challenges Patent-By-Patent Exclusivity
Sertraline Capsules Are Not Suitable For ANDA Due To Food Effect - Pfizer
Barr Fluoxetine Generic Exclusivity Claim Faces Hurdles
Lilly/Sepracor Prozac Agreement Suggests Limits Of FTC Patent Inquiries
Schering K-Dur Settlement With AHP Under Investigation By FTC
Advertisement
UsernamePublicRestriction

Register

PS035817

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel